Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of DTPa-HBV-IPV/Hib-MenC-TT vaccine in healthy infants
2008-006365-91Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2009
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus, Haemophilus influenzae type b, meningococcal C conjugate vaccine, pertussis filamentous haemagglutinin and Meningococcal group C polysaccharide conjugate vaccine in diphtheria, Tetanus, pertussis and 4 more (2 arms), sponsored by GSK. Primary endpoints: Immunogenicity one month after the second vaccine dose and Immunogenicity one month after the third vaccine dose. Started Jan 2009; status: completed.
02
Drugs
diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus, Haemophilus influenzae type b, meningococcal C conjugate vaccinepertussis filamentous haemagglutininMeningococcal group C polysaccharide conjugate vaccine
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on 2008-006365-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006365-91.